Legend Biotech (NASDAQ:LEGN – Get Rating) had its price objective lifted by analysts at JPMorgan Chase & Co. from $65.00 to $76.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would suggest a potential upside of 19.22% from the […]
Legend Biotech (NASDAQ:LEGN – Get Rating) had its price objective upped by HC Wainwright from $66.00 to $77.00 in a research report released on Thursday morning, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Legend Biotech’s Q1 2023 earnings at ($0.43) EPS, Q2 2023 […]
SG Americas Securities LLC increased its holdings in shares of Legend Biotech Co. (NASDAQ:LEGN – Get Rating) by 3.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 142,891 shares of the company’s stock after purchasing an additional 5,266 shares during the period. SG […]
Legend Biotech (NASDAQ:LEGN – Get Rating) had its target price lifted by equities research analysts at JPMorgan Chase & Co. from $65.00 to $76.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside […]
HC Wainwright reissued their buy rating on shares of Legend Biotech (NASDAQ:LEGN – Get Rating) in a report released on Wednesday, Benzinga reports. HC Wainwright currently has a $66.00 target price on the stock. LEGN has been the topic of several other research reports. Royal Bank of Canada initiated coverage on shares of Legend Biotech […]